Govt making new list of sick units for strategic stake sale, says Niti Aayog CEO Amitabh Kant

The govt expects to raise Rs 80,000 crore from PSU disinvestment in the next fiscal, lower than Rs 1 lakh crore raised this financial year

PTI February 21, 2018 15:50:13 IST
Govt making new list of sick units for strategic stake sale, says Niti Aayog CEO Amitabh Kant

New Delhi: Government think-tank NITI Aayog is preparing another list of sick PSUs that can be privatised, its CEO Amitabh Kant said on Wednesday.

The Prime Minister's Office (PMO) had asked the think- tank to look into the viability of sick state-run companies. The Aayog has already recommended strategic divestment of 40 sick public sector units.

"NITI Aayog has already recommended 40 sick PSUs for strategic disinvestment. Department of Investment and Public Asset Management (DIPAM) is working on it and the process is on advanced stage.

Govt making new list of sick units for strategic stake sale says Niti Aayog CEO Amitabh Kant

Amitabh Kant. Ibnlive

"...We have already sent four lists (of sick PSUs). We are working on the fifth list.We will also prepare sixth and seventh list (of sick PSUs)," Kant said here.

The government expects to raise Rs 80,000 crore from PSU disinvestment in the next fiscal, lower than Rs 1 lakh crore raised this financial year.

The 2017-18 Budget had set the target of disinvestment in public sector units at Rs 72,500 crore.

This included Rs 46,500 crore as disinvestment of CPSEs, Rs 15,000 crore from strategic disinvestment and Rs 11,000 crore from listing of insurance companies.

Updated Date:

also read

Adani Group takes over Thiruvananthapuram International Airport despite LDF, UDF protests
India

Adani Group takes over Thiruvananthapuram International Airport despite LDF, UDF protests

Kerala chief minister Pinarayi Vijayan had criticised the takeover, saying it was not for the development of the facility but to protect the interest of monopolies

Biological E seeks DCGI approval to conduct Phase 3 trials for Corbevax as booster dose for Covishield, Covaxin
India

Biological E seeks DCGI approval to conduct Phase 3 trials for Corbevax as booster dose for Covishield, Covaxin

Currently, phase 2/3 trials of the RBD protein sub-unit vaccine is underway and the results are likely to be declared this month.